Paper Details

  1. Home
  2. Paper Details

[A severe side effect of antitubercular therapy: pyrazinamide induced thrombocytopenia].

Author: BerardH, ChouaidC, LegodecJ, N'guyen Huy ThuyG, RocherF, RoseauJ-B

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study highlights a rare but serious side effect of pyrazinamide, an antitubercular drug, which is thrombocytopenia (low platelet count). This side effect can lead to bleeding and requires careful monitoring, especially in patients receiving multiple medications.
Paper Details　
Original Abstract of the Article :
The haematological side effects of antitubercular drugs are not well known. We report the observation of a patient who received Rifater for the treatment of pulmonary tuberculosis. After one month of treatment, he developed an acute pulmonary infection, with neutropenia (1218/microl) and thrombocyto...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0761-8425(08)74987-8

データ提供：米国国立医学図書館（NLM）

Pyrazinamide-Induced Thrombocytopenia: A Case Report

Navigating the desert of antitubercular therapy can be fraught with challenges, including potential side effects. This case report describes a patient who developed thrombocytopenia, a low platelet count, after receiving Rifater, a combination antitubercular drug containing pyrazinamide. The patient experienced an acute pulmonary infection, requiring suspension of antitubercular therapy. Upon reintroduction of the medication, thrombocytopenia recurred, leading to bleeding and requiring treatment with intravenous immunoglobulin. The patient's platelet levels improved after stopping pyrazinamide, confirming its role in inducing thrombocytopenia. This case report highlights the underreported risk of pyrazinamide-induced thrombocytopenia, a reminder that even seemingly safe medications can have unexpected side effects.

Pyrazinamide-Induced Thrombocytopenia: A Hidden Risk

This case report underscores the importance of being aware of potential side effects associated with antitubercular therapy. The findings highlight the need for close monitoring of platelet levels in patients receiving pyrazinamide and for early intervention if thrombocytopenia develops.

Anti-Tubercular Therapy: A Careful Approach

If you're undergoing antitubercular therapy, it's essential to be aware of potential side effects and to communicate any concerns with your healthcare provider. Close monitoring and prompt intervention can help manage complications effectively.

Dr.Camel's Conclusion

This case report highlights the need for vigilance in managing antitubercular therapy, particularly when it comes to potential side effects. The study underscores the importance of close monitoring and early intervention to minimize the risks associated with this treatment. Just as a desert traveler must be mindful of hidden dangers, healthcare providers and patients must remain vigilant in managing the potential complications of antitubercular therapy, ensuring a safe and effective path to recovery.

Date :
  1. Date Completed 2009-02-10
  2. Date Revised 2019-10-27
Further Info :

Pubmed ID

19106913

DOI: Digital Object Identifier

10.1016/s0761-8425(08)74987-8

Related Literature

Article Analysis
・Side Effects of pyrazinamide
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.